Genetica+ Gets CE-IVD Mark for Blood Test for Depression Treatments

October 21, 2022

Genetica+ has gained the CE-IVD mark for its NeuroKaire blood test which helps determine the optimal antidepressant treatment for major depressive disorder.

The test analyzes a blood sample for biomarkers using artificial intelligence and machine learning techniques.

In a recent 12-week study, the product demonstrated “unprecedented accuracy” in predicting drug response, the company said.

The Israel-based company is focused on developing solutions for psychiatric and neurological diseases.

View today's stories